von dem Borne P A, Meijers J C, Bouma B N
Department of Haematology, University Hospital Utrecht, The Netherlands.
Blood. 1995 Oct 15;86(8):3035-42.
Recently, an alternative pathway for factor XI activation has been described in which factor XI is activated by thrombin. Patients with a factor XI deficiency bleed mostly from tissues with high local fibrinolytic activity. Therefore, the role of thrombin-mediated factor XI activation in both fibrin formation and fibrinolysis was studied in a plasma system. Clotting was induced by the addition of tissue factor or thrombin to recalcified plasma in the presence or absence of tissue-type plasminogen activator, after which clot formation and lysis were measured using turbidimetry. Thrombin-mediated activation of factor XI was found to take place in plasma under physiologic conditions in the absence of a dextran sulfate-like cofactor. At high tissue factor concentrations, no effect of factor XI was seen on the rate of fibrin formation. Decreasing amounts of tissue factor resulted in a gradually increasing contribution of factor XI to the rate of fibrin formation. In addition, thrombin-mediated factor XI activation resulted in an inhibition of tissue-type plasminogen activator-induced lysis of the clot. This inhibition occurred even at tissue factor concentrations at which no effect of factor XI was observed on fibrin formation. Trace amounts of activated factor XI (1.25 pmol/L, representing 0.01% activation) were capable of completely inhibiting fibrinolysis in our system. The inhibitory effect was found to be mediated by thrombin that is additionally generated in a factor XI-dependent manner via the intrinsic pathway and is capable of protecting the clot against lysis. We also observed that formation of additional thrombin continued after the clot had been formed. We conclude that thrombin-mediated factor XI activation can take place in plasma. The presence of factor XI during coagulation results in the formation of additional thrombin within the clot capable of protecting this clot from fibrinolytic attack. The large amounts of thrombin that are formed by the intrinsic pathway via factor XI may play an important role in the procoagulant and thrombogenic state of clots and may therefore have important clinical and therapeutic implications.
最近,已描述了因子XI激活的另一条途径,其中因子XI由凝血酶激活。因子XI缺乏症患者大多从具有高局部纤维蛋白溶解活性的组织出血。因此,在血浆系统中研究了凝血酶介导的因子XI激活在纤维蛋白形成和纤维蛋白溶解中的作用。在存在或不存在组织型纤溶酶原激活剂的情况下,通过向重新钙化的血浆中添加组织因子或凝血酶来诱导凝血,之后使用比浊法测量凝块形成和溶解。发现凝血酶介导的因子XI激活在生理条件下的血浆中发生,且不存在硫酸葡聚糖样辅因子。在高组织因子浓度下,未观察到因子XI对纤维蛋白形成速率有影响。组织因子量的减少导致因子XI对纤维蛋白形成速率的贡献逐渐增加。此外,凝血酶介导的因子XI激活导致对组织型纤溶酶原激活剂诱导的凝块溶解的抑制。即使在未观察到因子XI对纤维蛋白形成有影响的组织因子浓度下,这种抑制也会发生。痕量的活化因子XI(1.25 pmol/L,代表0.01%的激活率)能够在我们的系统中完全抑制纤维蛋白溶解。发现这种抑制作用是由通过内源性途径以因子XI依赖性方式额外产生的凝血酶介导的,并且能够保护凝块免受溶解。我们还观察到在凝块形成后仍继续形成额外的凝血酶。我们得出结论,凝血酶介导的因子XI激活可在血浆中发生。凝血过程中因子XI的存在导致凝块内形成额外的凝血酶,能够保护该凝块免受纤维蛋白溶解攻击。通过内源性途径经由因子XI形成的大量凝血酶可能在凝块的促凝和血栓形成状态中起重要作用,因此可能具有重要的临床和治疗意义。